Nan Fung Group Holdings’s Travere Therapeutics TVTX Stock Holding History

Nan Fung Group Holdings’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,606	Closed	-$576K	–	47
2023 Q1	$576K	Hold	25,606	–	–	0.39%	31
2022 Q4	$538K	Buy	+25,606	New	+$543K	0.37%	26
2022 Q1	–	Sell	-48,500	Closed	-$1.5M	–	57
2021 Q4	$1.5M	Buy	+48,500	New	+$1.37M	0.45%	22

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Nan Fung Group Holdings's TVTX Position: Q2 2023 in Review

Nan Fung Group Holdings sold out of Travere Therapeutics (TVTX) in Q2 2023, closing a stake of 25,606 shares — an estimated $576K sold.

Nan Fung Group Holdings first reported a position in TVTX in Q4 2021 and held it in 3 quarters. The position peaked at $1.5M in Q4 2021. 169 funds tracked by Wall St. Rank hold TVTX as of Q2 2023.

Nan Fung Group Holdings reported no remaining Travere Therapeutics position as of Q2 2023 after selling out during the quarter.
Nan Fung Group Holdings sold 25,606 Travere Therapeutics shares in Q2 2023, an estimated $576K.
Nan Fung Group Holdings first reported a position in Travere Therapeutics in Q4 2021 and held it in 3 quarters.
Nan Fung Group Holdings's Travere Therapeutics position peaked at $1.5M in Q4 2021.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2023.

Based on Nan Fung Group Holdings's 13F filing for Q2 2023, filed 11 Aug 2023.